Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

A new study finds that obesity significantly reduces the effectiveness of urate-lowering therapy in male gout patients, with only 38.9% of obese patients reaching target serum urate levels compared to ...

After decades of studies, researchers from the University of the Philippines Manila (UPM) have developed a natural treatment ...

Febuxostat is a xanthine oxidase (XO) inhibitor, prescribed for gout and hyperuricemia (high level of uric acid in blood). The serum concentration of the active metabolites of Ambroxol ...

Among patients with hyperuricemia on hemodialysis, allopurinol significantly decreased cardiovascular risks, whereas febuxostat did not. Allopurinol and febuxostat both reduce death risk in ...

Doctor Edward Dwyer knows gout when he sees it ... Within the past few years a second agent, febuxostat, has become available and works in the exact same way. And finally an enzymatic protein ...

current drugs like allopurinol and febuxostat aren’t able to achieve that objective, and there are estimated to be around 160,000 people facing with refractory gout in the US. If approved ...